ESSA Pharma Statistics
Total Valuation
ESSA Pharma has a market cap or net worth of $228.03 million. The enterprise value is $92.23 million.
| Market Cap | 228.03M |
| Enterprise Value | 92.23M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ESSA Pharma has 44.36 million shares outstanding.
| Shares Outstanding | 44.36M |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 79.12% |
| Float | 25.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.71 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.89, with a Debt / Equity ratio of 0.00.
| Current Ratio | 32.89 |
| Quick Ratio | 32.67 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10,472.59 |
Financial Efficiency
Return on equity (ROE) is -19.50% and return on invested capital (ROIC) is -25.52%.
| Return on Equity (ROE) | -19.50% |
| Return on Assets (ROA) | -19.00% |
| Return on Capital (ROIC) | -25.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$554,682 |
| Employee Count | 50 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +83.57% in the last 52 weeks. The beta is 1.83, so ESSA Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | +83.57% |
| 50-Day Moving Average | 5.59 |
| 200-Day Moving Average | 6.57 |
| Relative Strength Index (RSI) | 45.73 |
| Average Volume (20 Days) | 33,638 |
Short Selling Information
| Short Interest | 1.01M |
| Short Previous Month | 883,110 |
| Short % of Shares Out | 3.78% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 15.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.15M |
| Pretax Income | -27.73M |
| Net Income | -27.73M |
| EBITDA | -27.63M |
| EBIT | -27.73M |
| Earnings Per Share (EPS) | -$0.63 |
Balance Sheet
The company has $136.15 million in cash and $353,662 in debt, giving a net cash position of $135.79 million or $3.06 per share.
| Cash & Cash Equivalents | 136.15M |
| Total Debt | 353,662 |
| Net Cash | 135.79M |
| Net Cash Per Share | $3.06 |
| Equity (Book Value) | 133.47M |
| Book Value Per Share | 3.01 |
| Working Capital | 133.12M |
Cash Flow
| Operating Cash Flow | -21.42M |
| Capital Expenditures | n/a |
| Free Cash Flow | -21.42M |
| FCF Per Share | -$0.48 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ESSA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.33% |
| Shareholder Yield | -0.33% |
| Earnings Yield | -12.16% |
| FCF Yield | -9.39% |
Analyst Forecast
The average price target for ESSA Pharma is $17.00, which is 230.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.00 |
| Price Target Difference | 230.74% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 8.73% |
Stock Splits
The last stock split was on April 25, 2018. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 25, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |